000276938 001__ 276938
000276938 005__ 20240229155007.0
000276938 0247_ $$2doi$$a10.1186/s12885-023-11056-1
000276938 0247_ $$2pmid$$apmid:37337133
000276938 0247_ $$2altmetric$$aaltmetric:150312328
000276938 037__ $$aDKFZ-2023-01215
000276938 041__ $$aEnglish
000276938 082__ $$a610
000276938 1001_ $$aChristakoudi, Sofia$$b0
000276938 245__ $$aA body shape index (ABSI) is associated inversely with post-menopausal progesterone-receptor-negative breast cancer risk in a large European cohort.
000276938 260__ $$aHeidelberg$$bSpringer$$c2023
000276938 3367_ $$2DRIVER$$aarticle
000276938 3367_ $$2DataCite$$aOutput Types/Journal article
000276938 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687357353_6280
000276938 3367_ $$2BibTeX$$aARTICLE
000276938 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276938 3367_ $$00$$2EndNote$$aJournal Article
000276938 520__ $$aAssociations of body shape with breast cancer risk, independent of body size, are unclear because waist and hip circumferences are correlated strongly positively with body mass index (BMI).We evaluated body shape with the allometric 'a body shape index' (ABSI) and hip index (HI), which compare waist and hip circumferences, correspondingly, among individuals with the same weight and height. We examined associations of ABSI, HI, and BMI (per one standard deviation increment) with breast cancer overall, and according to menopausal status at baseline, age at diagnosis, and oestrogen and progesterone receptor status (ER+/-PR+/-) in multivariable Cox proportional hazards models using data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.During a mean follow-up of 14.0 years, 9011 incident breast cancers were diagnosed among 218,276 women. Although there was little evidence for association of ABSI with breast cancer overall (hazard ratio HR = 0.984; 95% confidence interval: 0.961-1.007), we found borderline inverse associations for post-menopausal women (HR = 0.971; 0.942-1.000; n = 5268 cases) and breast cancers diagnosed at age ≥ 55 years (HR = 0.976; 0.951-1.002; n = 7043) and clear inverse associations for ER + PR- subtypes (HR = 0.894; 0.822-0.971; n = 726) and ER-PR- subtypes (HR = 0.906; 0.835-0.983 n = 759). There were no material associations with HI. BMI was associated strongly positively with breast cancer overall (HR = 1.074; 1.049-1.098), for post-menopausal women (HR = 1.117; 1.085-1.150), for cancers diagnosed at age ≥ 55 years (HR = 1.104; 1.076-1.132), and for ER + PR + subtypes (HR = 1.122; 1.080-1.165; n = 3101), but not for PR- subtypes.In the EPIC cohort, abdominal obesity evaluated with ABSI was not associated with breast cancer risk overall but was associated inversely with the risk of post-menopausal PR- breast cancer. Our findings require validation in other cohorts and with a larger number of PR- breast cancer cases.
000276938 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000276938 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276938 650_7 $$2Other$$aABSI
000276938 650_7 $$2Other$$aBody shape
000276938 650_7 $$2Other$$aBreast cancer
000276938 650_7 $$2Other$$aHip size
000276938 650_7 $$2Other$$aObesity
000276938 650_7 $$2Other$$aWaist size
000276938 650_7 $$04G7DS2Q64Y$$2NLM Chemicals$$aProgesterone
000276938 650_2 $$2MeSH$$aFemale
000276938 650_2 $$2MeSH$$aHumans
000276938 650_2 $$2MeSH$$aMiddle Aged
000276938 650_2 $$2MeSH$$aBody Mass Index
000276938 650_2 $$2MeSH$$aBreast Neoplasms: complications
000276938 650_2 $$2MeSH$$aRisk Factors
000276938 650_2 $$2MeSH$$aProgesterone
000276938 650_2 $$2MeSH$$aProspective Studies
000276938 650_2 $$2MeSH$$aTriple Negative Breast Neoplasms: complications
000276938 650_2 $$2MeSH$$aPostmenopause
000276938 650_2 $$2MeSH$$aSomatotypes
000276938 7001_ $$aTsilidis, Konstantinos K$$b1
000276938 7001_ $$aDossus, Laure$$b2
000276938 7001_ $$aRinaldi, Sabina$$b3
000276938 7001_ $$aWeiderpass, Elisabete$$b4
000276938 7001_ $$aAntoniussen, Christian S$$b5
000276938 7001_ $$aDahm, Christina C$$b6
000276938 7001_ $$aTjønneland, Anne$$b7
000276938 7001_ $$aMellemkjær, Lene$$b8
000276938 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b9$$udkfz
000276938 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b10$$udkfz
000276938 7001_ $$aSchulze, Matthias B$$b11
000276938 7001_ $$aMasala, Giovanna$$b12
000276938 7001_ $$aGrioni, Sara$$b13
000276938 7001_ $$aPanico, Salvatore$$b14
000276938 7001_ $$aTumino, Rosario$$b15
000276938 7001_ $$aSacerdote, Carlotta$$b16
000276938 7001_ $$aMay, Anne M$$b17
000276938 7001_ $$aMonninkhof, Evelyn M$$b18
000276938 7001_ $$aQuirós, J Ramón$$b19
000276938 7001_ $$aBonet, Catalina$$b20
000276938 7001_ $$aSánchez, Maria-Jose$$b21
000276938 7001_ $$aAmiano, Pilar$$b22
000276938 7001_ $$aChirlaque, María-Dolores$$b23
000276938 7001_ $$aGuevara, Marcela$$b24
000276938 7001_ $$aRosendahl, Ann H$$b25
000276938 7001_ $$aStocks, Tanja$$b26
000276938 7001_ $$aPerez-Cornago, Aurora$$b27
000276938 7001_ $$aTin Tin, Sandar$$b28
000276938 7001_ $$aHeath, Alicia K$$b29
000276938 7001_ $$aAglago, Elom K$$b30
000276938 7001_ $$aPeruchet-Noray, Laia$$b31
000276938 7001_ $$aFreisling, Heinz$$b32
000276938 7001_ $$aRiboli, Elio$$b33
000276938 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-023-11056-1$$gVol. 23, no. 1, p. 562$$n1$$p562$$tBMC cancer$$v23$$x1471-2407$$y2023
000276938 909CO $$ooai:inrepo02.dkfz.de:276938$$pVDB
000276938 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000276938 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000276938 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000276938 9141_ $$y2023
000276938 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-30
000276938 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-30
000276938 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-30
000276938 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-30
000276938 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2022$$d2023-10-24
000276938 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000276938 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000276938 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000276938 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-21T15:34:55Z
000276938 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-21T15:34:55Z
000276938 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2023-05-21T15:34:55Z
000276938 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000276938 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000276938 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000276938 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000276938 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000276938 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-24
000276938 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000276938 980__ $$ajournal
000276938 980__ $$aVDB
000276938 980__ $$aI:(DE-He78)C020-20160331
000276938 980__ $$aUNRESTRICTED